Top Gainers: NXT-ID Inc. (NASDAQ:NXTD), Durata Therapeutics Inc. (NASDAQ:DRTX), Ardelyx Inc. (NASDAQ:ARDX)
Dallas, Texas, 10/06/2014 (ustrademedia) – NXT-ID Inc. (NASDAQ:NXTD) announced the airings of the national ads on October 2 and October 3 during market hours on CNBC. The 30 second ads were aired during popular shows like Fast Money, Mad Money and Squawk Box to target interested consumers and investors. These ads are part of NXT-ID’s marketing initiatives to promote its patent-pending Wocket™, an innovative smart wallet. Wocket™ is designed to replace all the cards in one’s wallet including ATM, Credit, Debit, medical, insurance, ID, coupon and membership and virtually any card. Over 10,000 cards can be stored on Wocket™, which works with biometric stamp security.
Durata Therapeutics Inc. (NASDAQ:DRTX) announced that the U.S. FDA granted a Special Protocol Agreement for the design of its Phase III clinical trial of DALVANCE for injection. The study aims at comparing 1,500 mg single IV dose of dalbavancin with linezolid in patients with community-acquired pneumonia. Durata’s CEO, Paul R. Edick also expressed that the company is exploring the development of DALVANCE in other indications. Durata is currently testing this drug for ABSSSI (1,500 mg dosage regimen), pediatric osteomyelitis and pneumonia. DALVANCE’s approval for the treatment of ABSSSI in 1,000 mg dosing remarked the company’s transitioning to a commercial pharma company.
Ardelyx Inc. (NASDAQ:ARDX) announced positive results from its Phase II-b study related to tenapanor in patients with constipation-predominant IBS-C (irritable bowel syndrome). The study reported 60.7 percent increase in the CSBM (complete spontaneous bowel movement) responder rate in patients receiving 50 mg twice daily. This primary endpoint increased only 33.7 percent in patients receiving placebo. Most secondary endpoints also demonstrated clinically significant improvements. The drug tolerance was good in this randomized, multi-center study with safety profile in line with previous observations. Diarrhea and urinary tract infections were the most common adverse events noted in tenapanor-treated patients. The company estimates approximately 4.4 million people are suffering from IBS-C in the U.S. alone.